Long-term Histological Outcome in Patients with Chronic Hepatitis C Treated Repeatedly with Interferon alpha-2b without Sustained Response

References

• Di Bisceglie A, Goodman Z, Ishak K, Hoofnagle J, Melpolder J, Alter H. Long-term clinical and histopathological follow-up of chronic post transfusion hepatitis. Hepatology 1991; 14: 969–974
   PubMed Web of Science ®Google Scholar
• Mattsson L, Weiland O, Glaumann H. Long-term follow-up of chronic post-transfusion non-A, non-B hepatitis: clinical and histological outcome. Liver 1988; 8: 184–188
   PubMedGoogle Scholar
• Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero M L, Realdi G. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992; 16: 273–281
   PubMed Web of Science ®Google Scholar
• Wejstål R, Widell A, Norkrans G. Hepatitis C virus infection with progression to hepatocellular carcinoma: A report of five prospectively followed patients in Sweden. Scand J Infect Dis 1993; 25: 417–420
   PubMedGoogle Scholar
• Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H, Kawashima T. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797–1801
   PubMed Web of Science ®Google Scholar
• Di Bisceglie A, Martin P, Kassianides C, Lisker-Melman M, Murray L WJ, Goodman Z, Banks S, Hoofnagle J. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, doubleblind, placebo-controlled trial, N Engl J Med 1989; 321: 1506–1510
   PubMed Web of Science ®Google Scholar
• Davis G, Balart L, Schiff E, Lindsay K, Bodenheimer H, Perillo R, Carey W, Jacobson I, Payne J, Dienstag J, VanThiel D, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego T, Gibas A, hepatitis interventional therapy group. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989; 321: 1501–1506, and the
   PubMed Web of Science ®Google Scholar
• Schvarcz R, Weiland O, Wejstål R, Nokrans G, Fryden A, Foberg U. A randomized controlled open study of interferon alpha-2b treatment of chronic non-A, non-B posttransfusion hepatitis: no correlation of outcome to presence of hepatitis C virus antibodies. Scand J Infect Dis 1989; 21: 617–625
   PubMed Web of Science ®Google Scholar
• Reichard O, Foberg U, Frydén A, Mattsson L, Norkrans G, Sönnerborg A, Wejstål R, Yun Z B, Weiland O. High sustained response rate and clearance of viremia in chronic hepatitis C following tieatment with interferon alpha-2b for 60 weeks. Hepatology 1994; 19: 280–285
   PubMed Web of Science ®Google Scholar
• Shindo M, Di Bisceglie A, Cheung L, Wai-Kuo Shih J, Cristiano K, Feinstone S, Hoofnagle J. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 1991; 115: 700–704
   PubMed Web of Science ®Google Scholar
• Schvarcz R, Glaumann H, Weiland O, Norkrans G, Wejstål R, Frydén A. Histological outcome in interferon alpha-2b treated patients with chronic posttransfusion non-A, non-B hepatitis. Liver 1991; 11: 30–38
   PubMedGoogle Scholar
• Tine F, Magrin S, Craxi A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. J Hepatol 1991; 13: 192–199
   PubMed Web of Science ®Google Scholar
• Weiland O, Zhang Y, Widell A. Serum HCA RNA levels in patients with chronic hepatitis C given a second course of interferon alpha-2b treatment after relapse following initial treatment. Scand J Infect Dis 1993; 25: 25–30
   PubMedGoogle Scholar
• Yun Z B, Lindh G, Weiland O, Johansson B, Sönnerborg A. Detection of hepatitis C virus (HCV) RNA by PCR related to HCV antibodies in serum and liver histology in Swedish blood donors. J Med Virol 1993; 39: 57–61
   PubMed Web of Science ®Google Scholar
• Weiland O, Schvarcz R, Wejstål R, Norkrans G, Frydén A. Therapy of chronic posttransfusion non-A, non-B hepatitis with interferon alpha-2b: Swedish experience. J Hepatol 1990; 11: 57–62
   Web of Science ®Google Scholar
• International group. Acute and chronic hepatitis revisited. Lancet 1977; 2: 914–919
   PubMed Web of Science ®Google Scholar
• Knodell R G, Ishak K G, Black W C, Chen T S, Craig R, Kaplowitz N, Kiernan T W, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431–435
   PubMed Web of Science ®Google Scholar
• Mattsson L, Weiland O, Glaumann H. Application of a histological scoring system for assessment of histological outcome in patients with chronic posttransfusion non-A, non-B hepatitis with or without antibodies to hepatitis C. Liver 1990; 10: 257–263
   PubMedGoogle Scholar
• Hoofnagle J H, Di Bisceglie A M, Shindo M. Antiviral therapy of hepatitis C - present and future. J Hepatol 1993; 17: 130–136
   PubMed Web of Science ®Google Scholar
• Bartolomé J, Castillo I, Quiroga J A, Navas S, Carreno V. Detection of hepatitis C RNA in serum and peripheral blood mononuclear cells. J Hepatol 1993; 17: 90–93
   Web of Science ®Google Scholar
• Takehara T, Hayashi N, Mita E, Hagiwara H, Ueda K, Katayama K, Kasahara A, Fusamoto H, Kamada T. Detection of the minus strand of hepatitis C virus RNA by reverse transcription and polymerase chain reaction: Implications for hepatitis C virus replication in infected tissue. Hepatology 1992; 15: 387–390
   PubMed Web of Science ®Google Scholar
• Balart L A, Perrillo R, Roddenberry J, Regenstein F, Shim K S, Shieh C, Taylor B, Dash S, Gerber M A. Hepatitis C RNA in liver of chronic hepatitis C patients before and after interferon alfa treatment. Gastroenterology 1993; 104: 1472–1477
   PubMed Web of Science ®Google Scholar